Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement

Phase 4

Completed

Conditions: Hip Osteoarthritis

Interventions: Procedure: Lumbar plexus block
Procedure: Quadratus lumborum type 3 block
Drug: Ropivacaine injection

Registration Number: NCT03801265

Lead Sponsor: Sharad Khetarpal

Brief Summary: The Lumbar Plexus (LP) block is currently used as the standard-of-care regional anesthesia technique to provide postoperative pain management after primary hip replacement surgery at UPMC Shadyside Hospital. However, the LP technique is complex and can be associated with potentially serious side effects, including nerve injury, major bleeding, retroperitoneal hematoma, and intrathecal injection of local anesthetic. In rare instances the LP block can also lead to motor blockade, interfering with early ambulation. There are several case reports of Quadratus Lumborum inter-fascial block (QL3) giving equally adequate pain relief after total hip replacement surgery, and this QL3 block is performed routinely at this institution. The benefits to inter-fascial administration of local anesthetic include the avoidance of theoretical nerve injury, bleeding and intrathecal anesthetic administration associated with the direct interaction between the nerve and the nerve block needle. The purpose of this study is to show that QL3 block is non-inferior to the standard-of-care lumbar plexus block and should be used more regularly in hip replacement surgery. The study will be conducted as a prospective, randomized (1:1), double-blind, non-inferiority, active-comparator trial. The investigators plan to enroll 40 subjects, 20 in each treatment group. This study will prospectively investigate the efficacy of QL3 versus Classic LP block for post-operative pain management in subjects undergoing primary, unilateral hip replacement surgery and prospectively compare QL3 versus Classic LP block in time to mobilization and physical therapy response. Primary outcome measures include pain at rest and with movement at 6, 12 and 24 hours after surgery. Secondary outcomes will be time for first request for pain medication, total pain medications (narcotics and non-narcotic analgesics) given in 24 hours and the time of participant's ability to walk 100 feet as recorded by a physical therapist.

Detailed Description: Eligible patients will be approached for the study by the PI or Sub-I in the pre-operative area on their day of surgery. The anesthesiology investigator will speak with the patient about the study behind a closed drape and the patient will have adequate time to consider the consent and ask questions regarding risk factors associated with each type of block. Once consented, the patient will be randomized by computer generated random number to one of the two treatment groups. Once assigned the treatment allocation, only the clinician administering the block will be unblinded to the randomization outcome. If randomized to the LP block, an anesthesiologist on the Acute Interventional Perioperative Pain Service (AIPPS) will administer the block with this approach: Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 1 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.If randomized to the QL3 block, an anesthesiologist on the Acute Interventional Perioperative Pain Service (AIPPS) will administer the block with this approach:Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited. For both treatment groups, the local anesthetic used will be 100 mg 0.5% ropivacaine. After surgery, the patient will be followed by the blinded research team for incidence of adverse events, as well as the collection of the primary outcome measures. These include pain at rest and with movement at 6, 12 and 24 hours after surgery, time for first request for pain medication, total pain medications (narcotics and non-narcotic analgesics) given in 24 hours and the time of participant's ability to walk 100 feet as recorded by physical therapist. This information will be captured from the patient's electronic medical record.

Minor changes were made to the outcome measures after the original approval of this submission. This was only to clarify the specific measures from the more general descriptions in the original.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 46

Inclusion Criteria

Patients 18-90 years old
Primary unilateral total hip arthroplasty
BMI 20 - 36
Male and Female
All races

Exclusion Criteria

Patient refusal
ASA class > or = 4
Pregnancy
Any condition precluding patient going home with in 24 hours of surgery
Non-English speaking or inability to participate in the study
Patients with coagulopathy or on therapeutic anticoagulation
Chronic Steroid Use
Narcotic Addiction

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lumbar Plexus block	Lumbar plexus block	0.5% ropivacaine 100 mg (20 ml) will be injected
Lumbar Plexus block	Ropivacaine injection	0.5% ropivacaine 100 mg (20 ml) will be injected
Quadratus Lumborum type 3 block	Quadratus lumborum type 3 block	0.5% ropivacaine 100 mg (20 ml) will be injected
Quadratus Lumborum type 3 block	Ropivacaine injection	0.5% ropivacaine 100 mg (20 ml) will be injected

Primary Outcome Measures

Name	Time	Method
Pain at Rest After Surgery	24 hours after surgery	Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain at rest. A higher score means worse outcomes.
Pain With Movement After Surgery	24 hours after surgery	Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain with movement. A higher score means worse outcomes.

Secondary Outcome Measures

Name	Time	Method
Pain During Physical Therapy	24 hours after surgery	Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain with movement. A higher score means worse outcomes.
Total Acetaminophen Consumption During 24 Hours After Surgery	24 hours after surgery	Patient electronic medical records were reviewed for total acetaminophen consumption during 24 hours after surgery in milligrams (mg)
Total Celecoxib Consumption During 24 Hours After Surgery	24 hours after surgery	Patient electronic medical records were reviewed for total celecoxib consumption during 24 hours after surgery in milligrams (mg)
Postoperative Time to Accomplish Walking 100 Feet	within 24 hours after surgery	This measurement is from T0 being out of surgery room time to the point at which the participant was able to walk 100 feet during the first day post-surgery. Values were abstracted from the patient medical records.
Block Procedure Duration	during surgery	Duration that the patient underwent the block procedure during surgery in minutes
Patients With Postoperative Quadriceps Weakness	12 hours after surgery	patients who report having post-surgical quadriceps weakness.
Total Opioid Consumption During 24 Hours After Surgery	24 hours after surgery	Narcotics will be converted to oral morphine equivalents
Total Ketorolac Consumption During 24 Hours After Surgery	24 hours after surgery	Patient electronic medical records were reviewed for total ketorolac consumption during 24 hours after surgery in milligrams (mg)
Total Gabapentin Consumption During 24 Hours After Surgery	24 hours after surgery	Patient electronic medical records were reviewed for total gabapentin consumption during 24 hours after surgery in milligrams (mg)
Total Oral Ketamine Consumption During 24 Hours After Surgery	24 hours after surgery	Patient electronic medical records were reviewed for total oral ketamine consumption during 24 hours after surgery in milligrams (mg)
Opioid Consumption During 0-6 Hours After Surgery	6 hours after surgery	Narcotics will be converted to oral morphine equivalents
Opioid Consumption During 6-12 Hours After Surgery	6-12 hours after surgery	Narcotics will be converted to oral morphine equivalents
Opioid Consumption During 12-24 Hours After Surgery	12-24 hours after surgery	Narcotics will be converted to oral morphine equivalents